BE-STRONG HCM: Biomarkers, Exercise Stress Testing, and MRI to Obtain New InsiGhts in Hypertrophic CardioMyopathy - Troponin in hypertrophic cardiomyopathy and mutation carriers

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Patients with an echocardiographically proven hypertrophic cardiomyopathy according to the ESC guidelines;
•Individuals with a HCM associated mutation without the clinical characteristics of hypertrophic cardiomyopathy (pre-clinical HCM patients);
•Age >= 18 years;
•Able to comply with the protocol;
•Written informed consent.

•Known significant epicardial coronary artery disease;
•Patients with LVH in the clinical setting of other disorders that explain the myocardial hypertrophy (amyloidosis, MELAS, Anderson-Fabry, WPW etc.);
•Heart failure NYHA class III-IV;
•Patients with known hemodynamic instability or syncope during exercise due to left ventricular
•outflow gradient or occurrence of ventricular arrhythmia;
•History of PTSMA (percutaneous transluminal septal myocardial ablation) or Morrow myectomy;
•Patients not able to complete a bicycle test;
•Any contraindication to MR imaging (MR imaging is not obligatory for assessment of the primary objective, therefore relative exclusion criterion);
•Recent (within 30 days) admittance to the hospital for any cardiac reason (myocardial infarction, heart failure, cardiac arrhythmia, etc.);
•Severe renal insufficiency (eGFR < 30 ml/min);
•Any other condition which, in the opinion of the investigator, may pose a significant hazard to the subject if he or she participates in the present study.

发起方

niversitair Medisch Centrum Sint Radboud